Brains Bioceutical Corp. (“Brains Bio”), a global life sciences company advancing a clinically validated portfolio of therapeutic and pharmaceutical programs, today announced the appointment of Dr.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular ...

Campus hiring in India is showing early strain as AI boosts productivity and the West Asia conflict dampens demand. Firms ...

As cell and gene therapies (CGTs) continue to receive regulatory approvals at an accelerating pace, health care institutions ...

The first biosimilars referencing Humira became available in 2023. That year, 10 FDA-approved adalimumab are now on the ...

The global Automated Cage Handling Systems Market is entering a rapid expansion phase as laboratory animal research ...